Outset Medical exceeded earnings expectations, showcased operational efficiency and financial improvement, aiming for market growth.

From Nasdaq: 2025-02-19 18:22:05

Outset Medical (NASDAQ: OM) exceeded fourth-quarter earnings expectations with revenue of $29.5 million, surpassing the projected $28 million, and an adjusted EPS loss of $0.37, beating the estimated loss of $0.44. The company showcased improved operational efficiency and financial metrics. With a focus on the innovative Tablo Hemodialysis System, Outset Medical aims to enhance market penetration and drive revenue growth. Gross margins saw a significant increase to 37.7%, operating expenses were reduced by 28%, and recurring revenue from services grew by 17%. The company remains optimistic about sustained growth and profitability in the future, with revenue projections for 2025 ranging from $115 million to $125 million.



Read more at Nasdaq: Outset Medical: Profitability Path Brightens